Skip to main content
. Author manuscript; available in PMC: 2013 Jan 11.
Published in final edited form as: Diabetologia. 2012 Feb 15;55(5):1446–1457. doi: 10.1007/s00125-012-2477-5

Figure 3.

Figure 3

Dose-related effects of "PKC-ι/λ inhibitors, ICAPP (panels a and d) and ATM (panels c and f) on basal (open bars) and insulin-stimulated (shaded bars) activities of total aPKC and Akt2 in hepatocytes of non-diabetic humans. Incubation time, 4 hours with or without 1µmol/l insulin. Also shown are dose-related effects of ICAPP on: (1) activity of 10ng recombinant "PKC-ι activated by maximally-effective 10fmol/l PIP3 (panel b), and (2) serine-256 phosphorylation of FoxO1 in hepatocytes (panel e). Values are mean ± SEM of 4 or more determinations.

HHS Vulnerability Disclosure